SMD Pharmacy Ltd 11485547 false 2024-08-01 2025-07-31 2025-07-31 The principal activity of the company is providing pharmacy services. Digita Accounts Production Advanced 6.30.9574.0 true true 11485547 2024-08-01 2025-07-31 11485547 2025-07-31 11485547 core:CurrentFinancialInstruments 2025-07-31 11485547 core:CurrentFinancialInstruments core:WithinOneYear 2025-07-31 11485547 core:Non-currentFinancialInstruments core:AfterOneYear 2025-07-31 11485547 core:Goodwill 2025-07-31 11485547 core:MotorVehicles 2025-07-31 11485547 core:PlantMachinery 2025-07-31 11485547 1 2025-07-31 11485547 bus:SmallEntities 2024-08-01 2025-07-31 11485547 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 11485547 bus:FilletedAccounts 2024-08-01 2025-07-31 11485547 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 11485547 bus:RegisteredOffice 2024-08-01 2025-07-31 11485547 bus:Director1 2024-08-01 2025-07-31 11485547 bus:Director2 2024-08-01 2025-07-31 11485547 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 11485547 core:Goodwill 2024-08-01 2025-07-31 11485547 core:MotorVehicles 2024-08-01 2025-07-31 11485547 core:PlantMachinery 2024-08-01 2025-07-31 11485547 core:Vehicles 2024-08-01 2025-07-31 11485547 countries:AllCountries 2024-08-01 2025-07-31 11485547 1 2024-08-01 2025-07-31 11485547 2024-07-31 11485547 core:Goodwill 2024-07-31 11485547 core:MotorVehicles 2024-07-31 11485547 core:PlantMachinery 2024-07-31 11485547 1 2024-07-31 11485547 2023-08-01 2024-07-31 11485547 2024-07-31 11485547 core:CurrentFinancialInstruments 2024-07-31 11485547 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 11485547 core:Non-currentFinancialInstruments core:AfterOneYear 2024-07-31 11485547 core:Goodwill 2024-07-31 11485547 core:MotorVehicles 2024-07-31 11485547 core:PlantMachinery 2024-07-31 11485547 1 2024-07-31 11485547 1 2023-08-01 2024-07-31 11485547 1 2023-07-31 iso4217:GBP xbrli:pure

Registration number: 11485547

SMD Pharmacy Ltd
Unaudited Filleted Financial Statements
for the Year Ended 31 July 2025

SMD Pharmacy Ltd

Contents

Statement of Financial Position | 1 to 2
Notes to the Unaudited Financial Statements | 3 to 9

SMD Pharmacy Ltd

(Registration number: 11485547)
Statement of Financial Position as at 31 July 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Intangible assets | 4 | 2,250 | 3,000
Tangible assets | 5 | 28,302 | 40,901
|  | 30,552 | 43,901
Current assets |  |  |
Stocks |  | 15,000 | 15,000
Debtors | 6 | 159,063 | 31,749
Cash at bank and in hand |  | 235,987 | 164,179
|  | 410,050 | 210,928
Creditors: Amounts falling due within one year | 7 | (265,529) | (175,340)
Net current assets |  | 144,521 | 35,588
Total assets less current liabilities |  | 175,073 | 79,489
Creditors: Amounts falling due after more than one year | 7 | (24,890) | (30,309)
Provisions for liabilities |  | (1,740) | (525)
Net assets |  | 148,443 | 48,655
Capital and reserves |  |  |
Called up share capital |  | 2 | 2
Profit and loss account |  | 148,441 | 48,653
Shareholders' funds |  | 148,443 | 48,655

For the financial year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Statement of Comprehensive Income.

Approved and authorised by the Board on 26 January 2026 and signed on its behalf by:

SMD Pharmacy Ltd

(Registration number: 11485547)
Statement of Financial Position as at 31 July 2025 (continued)

Saray Mielgo-Darriba Director
Harrison Perrin Director

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

1 | General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
The Basement The Medical Centre
St Brannocks Road
Ilfracombe
Devon
EX34 8EG
England

Principal activity

The principal activity of the company is providing pharmacy services.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling which is the functional currency of the entity.

Going concern

The financial statements have been prepared on a going concern basis.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome.

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

2 | Accounting policies (continued)

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 4 Years Straight Line
Motor Vehicles | 4 Years Straight Line

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

2 | Accounting policies (continued)

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class | Amortisation method and rate
Goodwill | 10 Years Straight Line

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Costs include all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition. .
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the statement of comprehensive income over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

2 | Accounting policies (continued)

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.
Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the statement of financial position as a finance lease obligation.
Lease payments are apportioned between finance costs in the statement of comprehensive income and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Recognition and measurement
A financial asset or a financial liability is recognised only when the company becomes party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 7 (2024 - 7).

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

4 | Intangible assets

| Goodwill £ | Total £
Cost or valuation
At 1 August 2024 | 5,000 | 5,000
At 31 July 2025 | 5,000 | 5,000
Amortisation
At 1 August 2024 | 2,000 | 2,000
Amortisation charge | 750 | 750
At 31 July 2025 | 2,750 | 2,750
Carrying amount
At 31 July 2025 | 2,250 | 2,250
At 31 July 2024 | 3,000 | 3,000

5 | Tangible assets

| Plant and machinery £ | Motor vehicles £ | Total £
Cost or valuation
At 1 August 2024 | 5,433 | 51,923 | 57,356
Additions | 1,788 | - | 1,788
At 31 July 2025 | 7,221 | 51,923 | 59,144
Depreciation
At 1 August 2024 | 3,474 | 12,981 | 16,455
Charge for the year | 1,406 | 12,981 | 14,387
At 31 July 2025 | 4,880 | 25,962 | 30,842
Carrying amount
At 31 July 2025 | 2,341 | 25,961 | 28,302
At 31 July 2024 | 1,959 | 38,942 | 40,901

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

6 | Debtors

| 2025 £ | 2024 £
Trade debtors | 123,756 | -
Other debtors | 34,080 | 30,953
Prepayments | 1,227 | 796
| 159,063 | 31,749

7 | Creditors

Creditors: amounts falling due within one year

| 2025 £ | 2024 £
Due within one year |  |
Loans and borrowings | 7,594 | 6,549
Trade creditors | 127,615 | 72,667
Taxation and social security | 63,692 | 30,658
Accruals and deferred income | 2,650 | 1,582
Other creditors | 63,978 | 63,884
| 265,529 | 175,340

Creditors: amounts falling due after more than one year

| 2025 £ | 2024 £
Due after one year |  |
Loans and borrowings | 24,890 | 30,309

8 | Reserves

Profit and loss account:
This reserve records retained earnings and accumulated losses.

SMD Pharmacy Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025 (continued)

9 | Related party transactions

Transactions with directors

2025 | At 1 August 2024 £ | Advances to director £ | At 31 July 2025 £
Directors Loan | (63,885) | (93) | (63,978)

2024 | At 1 August 2023 £ | Advances to director £ | At 31 July 2024 £
Directors Loan | (92,614) | 28,729 | (63,885)